Latest news & insights
Boyds launches Regulatory Operations service
Boyds are excited to announce the expansion of its service offering with the launch of a new in-house regulatory operations service that will enable the company to support the full lifecycle of its clients’ drug development projects.
Karen Mullen recognised as a Global Fellow in Medicines Development
We are delighted to congratulate Chief Medical Officer at Boyds, Dr Karen Mullen, on being recognised as a Global Fellow in Medicines Development (GFMD) by the Academy of Global Medicines Development Professionals.
Boyds expands regulatory affairs team in the US
Boyds is delighted to announce the appointment of regulatory affairs professional Eric Hardter to our US team.
#AgileLeaders Forum on Successful Development of C&G Therapies
We are excited to announce our involvement in the upcoming #AgileLeaders Forum on Successful Development of C&G Therapies, with special guest speaker, Professor Alan Boyd.
Boyds announced as Proud Patron of CAT FM
The Cat, local radio station for Crewe and Nantwich, has announced a partnership with Boyds, global drug development consultancy.
CTD to CTR: Clinical Trials Regulation: ongoing trials beyond 31 January 2025
If you are running any clinical trials, approved under the Clinical Trials Directive, that will continue to run after 31 January 2025, you will need to comply with the Clinical Trials Regulation (Regulation (EU) No 536/2014)
Boyds announces trio of promotions
Our leading Regulatory Affairs Group has promoted Dr Sabine Rühle to Director of Regulatory Affairs and Navila Rehman to Senior Manager, Quality Assurance and Regulatory Operations.
Dr Karen Mullen awarded Fellowship of the Royal College of Physicians
Boyds’ Chief Medical Officer Dr Karen Mullen has been awarded Fellowship of the Royal College of Physicians. The prestigious award recognises Karen’s standout contribution to
